Greenwich LifeSciences announced that an abstract on its Phase III trial FLAMINGO-01, evaluating the immunotherapy GLSI-100 to prevent breast cancer recurrence, has been accepted for presentation at the 2026 ASCO Annual Meeting. Preliminary data from the non-HLA-A*02 arm shows a 70-80% reduction in recurrence rates, consistent with earlier Phase IIb results. The company plans to share full data at the conference and continue participation in upcoming oncology and investor events. This milestone highlights progress in developing a potentially effective treatment for HER2 positive breast cancer patients.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum (ETH) has outperformed Bitcoin (BTC) in Q3, driven by a rally sparked by a softer CPI report and strong on-chain metrics. The recent surge pushed ETH above $1,900, triggering significant liquidations in futures positions. However, ETH now fa...
Solana's number of wallets holding tokenized real-world assets (RWAs) has exceeded 300,000, surpassing Ethereum's roughly 200,000 holders. While Solana's RWA value doubled in 2026 to $3.45 billion, Ethereum still leads with $16.3 billion in tokenized...
Baidu's board has approved a plan to convert to a dual-primary listing on the Hong Kong Stock Exchange's Main Board, alongside its existing Nasdaq listing. This move aims to enhance the liquidity of Baidu's shares, broaden its investor base, and prov...
